Document is current
Any future updates will be listed below
-
Authors
Pazmino, Sofia https://orcid.org/0000-0001-8579-6914
Schmid, Stefanie https://orcid.org/0009-0005-5929-3519
Blanch, Jordi https://orcid.org/0000-0001-8211-3292
Coral, Daniel https://orcid.org/0000-0002-8809-4544
Steenackers, Nele
Forestier, Nicole
Gallardo-Nuell, Laura https://orcid.org/0009-0008-3004-1571
Zhang, Naichuan https://orcid.org/0009-0002-0958-3903
Reinhart-Steininger, Birgit
Leal, Yenny https://orcid.org/0000-0003-1926-1844
van Laar, Amar https://orcid.org/0000-0003-1289-0955
Ramos, Rafael
Bharadwaj Araveti, Shreekar https://orcid.org/0009-0002-9818-2959
Heidemann, Ditte F. https://orcid.org/0000-0003-4315-5793
Nowak, Kinga https://orcid.org/0009-0003-0517-5344
Rosen, Jonathan https://orcid.org/0009-0001-4409-7110
Hurtado del Pozo, Carmen
Möller, Christian-Dominik
Mathieu, Chantal
le Roux, Carel W. https://orcid.org/0000-0001-5521-5445
Franks, Paul W. https://orcid.org/0000-0002-0520-7604
Fernandez-Real, Jose Manuel https://orcid.org/0000-0002-7442-9323
Lanzinger, Stefanie
Van der Schueren, Bart https://orcid.org/0000-0003-4754-784X
- License Information
-
More Information
Article History
Received: 12 May 2025
Accepted: 7 April 2026
First Online: 16 April 2026
Competing interests
: C.M. serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Boehringer Ingelheim, Bayer, Roche, Medtronic, Imcyse, Insulet, Biomea Fusion, and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for C.M. from Medtronic, Imcyse, Novo Nordisk, Sanofi, and ActoBio Therapeutics; C.M. serves or has served on the Speaker’s bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. C.M. is the president of EASD. All external support of EASD is to be found on . The remaining authors declare no competing interests.
